Prevalence and Characterization of Hepatitis C Virus in Hemodialysis Patients

Takashi Morikawa, Keisuke Nakata, Keisuke Hamasaki, Shohtaro Tsuruta, Yuji Kato, Kazuhiko Nakao*, Toshio Ohtsubo** and Katsumi Eguchi

Object Chronic hepatitis C virus (HCV) infection is common in hemodialysis (HD) patients. In the present study, the prevalence and properties of HCV in HD patients were analyzed. Methods and Results Of 125 HD patients, 34 (27%) were positive for antibody to HCV, and HCV-RNA was detected in 23 (68%) of the 34 patients using reverse transcription polymerase chain reaction. The HCV-RNA sequence analysis did not identify the alterations specific to HD patients with HCV, although one patient had a variant virus containing the deletion of the core gene sequence. When serial changes in the levels of HCV-RNA were evaluated in 15 patients by a branched DNA assay, the values decreased immediately after HD procedure, but returned to the baseline values 2 days after the procedure. Conclusion These results indicate that HCV in HD patients is replication-competent, although a transient reduction in the levels of HCV-RNA occurs during HD.

Key words: hypervariable region 1, core gene sequence, polymerase chain reaction (PCR)

Introduction

Chronic hepatitis C virus (HCV) infection is a common problem in patients who receive hemodialysis (HD). In fact, previous studies have demonstrated that as many as 10 to 40% of HD patients are chronically infected by HCV, although HCV prevalence in HD patients is highly variable among different countries and even among HD units in the same area (1−3). The high prevalence of HCV in HD patients is believed to be attributed to the transfusion of HCV-contaminated blood products before the availability of reliable HCV screening. In addition, some investigators have shown that the length of time on HD is an independent predictor of HCV infection in chronic HD patients (4, 5). This finding suggests nosocomial transmission of HCV within HD units.

Patients

One hundred and twenty-five patients who received HD for 1 to 24 years (mean, 9.8) in Kouseikai Hospital, Nagasaki, Japan were studied. The sample population included 61 men and 64 women, and they were 27 to 88 years of age (mean, 55).

The causes of chronic renal failure were chronic glomerulonephritis in 19 patients, diabetic nephropathy in 14, polycystic kidney disease in 11, and hypertension in 12.

For editorial comment, see also p 615.

From the First Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, *Health Research Center, Nagasaki University, Nagasaki and **Kouseikai Hospital, Nagasaki

Received for publication September 24, 1998; Accepted for publication February 23, 1999

Reprint requests should be addressed to Dr. Takashi Morikawa, the First Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501

(Internal Medicine 38: 626−631, 1999)

Key words: hypervariable region 1, core gene sequence, polymerase chain reaction (PCR)
phritis (n=79), diabetic nephropathy (n=9), chronic pyelonephritis (n=9), polycystic kidney disease (n=5), lupus nephritis (n=2), amyloidosis (n=1) and unknown etiology (n=20). All patients received HD treatment for 4–5 hours 3 times a week. The serum levels of alanine aminotransferase (ALT) were regularly measured before each HD procedure at a 1 month interval. Tests for hepatitis B surface antigen (HBsAg) and antibody to HCV (anti-HCV, 2nd generation) were performed in all patients using commercially available enzyme-linked immunosorbent assay kits (Dainabot and Ortho Diagnostic Systems, respectively). The serum samples immediately before and after HD procedure and 2 days after the procedure were obtained from each patient with informed consent and stored at -40°C for later analysis of the HCV genomes.

**Qualitative and quantitative analyses of HCV.**

The serum samples taken immediately before HD procedure were subjected to analysis for the presence of HCV-RNA by RT-PCR using a commercially available kit (Amplitcor, Roche Diagnostic Systems). In patients who were positive for HCV-RNA by RT-PCR, HCV genotypes were determined by the method described previously by Okamoto et al (9). The genomic variations in the hypervariable region 1 (HVR1) existing in the putative E2/NS-1 domain and the core region of HCV were analyzed by using the PCR-single strand conformation polymorphism (PCR-SSCP) assay and direct sequencing, respectively. In the PCR-SSCP assay, the sequence encompassing HVR1 was amplified by the nested PCR using the two sets of primers, external sense primer (nucleotide 1284–1304), 5′-GCAATGGGACATGATGATCAACTGG-3′, internal antisense primer (nucleotide 1847–1867), 5′-AGTTACTCCGGATCCCACAA-3′, and internal sense primer (nucleotide 927–956), 5′-GTTCGTGACATGGTATCCCGGACACGTT-3′ (10, 11). The PCR product (257 bp in size) was diluted to 1/16 (vol/vol) with a solution containing 98% formamide and 20 mmol/l ethylenediaminetetraacetic acid, heat-denatured at 80°C for 5 minutes, chilled on ice, and subjected to electrophoresis in a 10% to 20% density gradient polyacrylamide gel at 300 V for 3 hours at 10°C. The separated bands on the gel were visualized with silver staining. Since heterogeneous mixtures of mutant genomes are separated into different bands depending on sequence-specific conformations by this assay, the degree of polymorphism (PCR-SSCP) assay and direct sequencing was performed for 40 cycles, in which each cycle included denaturation at 94°C for 1 minute, annealing at 60°C for 1 minute, and primer extension at 72°C for 1 minute. Residual dNTPs and oligonucleotide primers were removed by centrifugation filtration columns (Suprec-02; Takara, Kyoto). Nucleotide sequences were directly determined by the dideoxy chain termination method using the Taq Dye Primer Cycle Sequencing Kit (Applied Biosystems, Ink., Foster, CA) and the Applied Biosystems Model 373A DNA Sequencing System (Applied Biosystems, Ink.) (12).

The serum levels of HCV-RNA were measured by a branched DNA (bDNA) assay (Chiron Corp.). This assay involves the hybridization of synthetic oligonucleotides to the highly conserved 5′ noncoding region and the core gene of the HCV RNA (13). The detection limit of this assay was 0.50 x 10^6 HCV genome equivalents per milliliter (0.5 mEq/ml). When patients had HCV-RNA levels of 0.5 mEq/ml (a detection limit) or more in the serum samples taken immediately before the HD procedure, the levels of HCV-RNA immediately and 2 days after HD procedure were also measured by a bDNA assay.

**Statistical Analysis.**

Results are expressed as mean±SD. Comparisons were performed with Student’s t test and the chi-square test. All P values were two-tailed, and P values of less than 0.05 were considered to indicate statistical significance.

**Results**

**Prevalence rates of anti-HCV and HCV-RNA in HD patients**

Of 125 HD patients, 34 (27%) were positive for anti-HCV, and 23 (68%) of these 34 patients were also positive for HCV-RNA by RT-PCR. HCV-RNA could not be detected in any patients who were negative for anti-HCV (Table 1). The mean age and sex ratios were almost similar in anti-HCV-positive and -negative patients. However, the duration of HD in anti-HCV-positive patients was significantly longer than that in anti-HCV-negative patients (p<0.01), while the difference was not significant in HCV-RNA-positive and -negative patients with anti-HCV. Thirty-one (91%) of 34 anti-HCV-positive patients had histories of blood transfusions, as did 55 (60%) of anti-HCV-negative patients (p<0.01). HCV screening in blood donors started in 1989 in Japan. Considering evaluation of the time of blood transfusion in each case, 30 of 31 patients who had histories of blood transfusions and were positive for anti-HCV received blood transfusions before 1989. The levels of serum ALT were monitored monthly for more than 1 year in all patients. The values were consistently within the normal limit (less than 35 IU/l) in a large proportion of the patients irrespective of the positivities of anti-HCV or HCV-RNA. One (3%) of 34 anti-HCV-positive patients and 5 (5%) of 91 anti-HCV-negative patients were positive for HBsAg.
Variations of HCV in HD patients

To investigate the variations of HCV in HD patients, the sequences of HVR1 and the core region of HCV were analyzed. In 21 of 23 patients who were positive for HCV-RNA, serum samples were available for analysis of the HVR1 quasispecies by the PCR-SSCP assay. As shown in Fig. 1, the number of bands separated on the gel corresponding to the degree of the HVR1 quasispecies complexity was widely varied, ranging from 1 to 8 (mean, 3.8) in each patient.

The sequence of the HCV core region could be analyzed in 16 of 19 patients with HCV1b by direct sequencing. In comparison with the amino acid sequence of HCJ4 strain used as a reference sequence, the amino acid substitutions were found mainly in the median portion of the core protein in HD patients (Fig. 2). However, the alterations relevant to HD patients with HCV could not be identified, although one patient had a variant virus which contained a deletion of the core gene sequence between nucleotide 114 and nucleotide 326, resulting in a deletion of the amino acid sequence between the 39th codon.

Figure 1. Variations of hypervariable region 1 (HVR1) of HCV were analyzed in 21 of 23 hemodialysis patients who were positive for HCV-RNA. The degree of complexity of HVR1 quasispecies was assessed by the number of bands on PCR-SSCP analysis as described in Materials and Methods.

Figure 2. Analysis of HCV core region sequences in 16 hemodialysis patients with HCV1b. The amino acid sequence of the HCJ4 strain is shown as a reference sequence in the upper column. The asterisks indicate the deleted sequence of the HCV core region in one patient (case 16).
HCV in Hemodialysis Patients

Figure 3. Time course analysis of HCV-RNA levels in 15 hemodialysis patients. The levels of HCV-RNA were measured by a branched DNA (bDNA) assay. To ensure that association was not dependent on the computation level, the analysis was done with bDNA assay-negative samples set at 0.5 mEq/ml. The HCV-RNA level immediately after HD procedure (mean ± SD, 3.9 ± 8.2 mEq/ml) was significantly lower than those at baseline and at 2 days after HD procedure (mean ± SD, 6.5 ± 12.7 mEq/ml and 7.8 ± 13.7 mEq/ml, p<0.05, respectively).

Discussion

Chronic HCV infection affects approximately 30% of patients on maintenance HD (1–3). The majority of HD patients with HCV have only a minimal derangement in the ALT level (1, 6). However, recent histological analysis of the liver tissue indicates that HD patients with HCV often have chronic active hepatitis or cirrhosis (7, 8). The serum level of vitamin B6 which is indispensable for the measurement of ALT activity is reduced in HD patients (14). This results in relatively low levels of serum ALT in HD patients despite the presence of progressive liver disease in some of these patients. In addition, the patients with normal liver enzyme levels during HD can still develop progressive liver disease after renal transplantation (5, 15). Expression of interleukin-1 β and tumor necrosis factor-α (TNF-α) as well as expression of their inhibitors such as interleukin-10 and soluble receptors of TNF-α have been shown to be elevated in HD patients (16, 17). Such an imbalance between cytokines and their inhibitors may play a pivotal role in the multifaceted process of immune dysfunction in HD patients. Therefore, characterization of HCV in HD patients is of importance for the understanding and management of the virus-associated inflammatory liver disease in these patients.

In the present study, the prevalence rate of anti-HCV in 125 HD patients was 27%. The rate was higher in patients who received HD for a relatively longer period, suggesting the risk of nosocomial transmission of HCV within the HD unit as reported previously (18, 19). Taken together, HCV infection acquired by blood transfusions without HCV screening appears to be the main cause of the viral transmission in HD patients, because approximately 88% of anti-HCV-positive patients had a history of blood transfusions before HCV screening in the present study. Of 34 HD patients with anti-HCV, 23 (68%) were also positive for HCV-RNA by RT-PCR. This is consistent with the results described previously, where serum HCV-RNA was detected in approximately 80% of HD patients who were positive for anti-HCV (1–3). Of 23 HCV-RNA-positive patients, 19 (83%) had the viral genotype lb, which was relatively similar to recent results in Japan, where HCV lb was found in approximately 70% of patients with HCV (9). Since intermittent hepatitis C viremia in HD patients was reported previously (20), a single negative result does not reflect spontaneous remission. Accordingly, the regular follow-up studies including serial testing for the presence of HCV-RNA by RT-PCR will be necessary in HD patients who are positive for anti-HCV but negative for HCV-RNA as well as patients who are positive for both.

In the HCV-RNA sequence analysis, the complexity of HVR1 quasispecies was evaluated by the PCR-SSCP assay. The degree of the HVR1 quasispecies complexity assessed by the number of bands in HD patients with HCV was nearly similar to that reported previously in patients with chronic hepatitis C who did not receive HD (10, 21). Antibodies directed to HVR1 of HCV have recently been shown to neutralize the corresponding HCV isolate in vitro (22). Moreover, recent studies have shown that the sequences of HVR1 of HCV found in earlier time points of infection are rapidly mutated during chronic infection because of an immune escape of newly arising viral variants of HVR1 (23). These results suggest that the appearance of viral variants of HVR1 is associated with viral persistence in patients who do and do not receive HD. The HCV
core gene sequences were also analyzed in this study. The amino acid substitutions were found in each patient. However, no particular substitutions relevant to HD patients with HCV were elucidated, although it is noteworthy that one patient had a variant virus containing the deletion of the core gene sequence. The deletion mutant and the full length HCV would be co-infected in the same hepatocyte and would synthesize viral particles as seen in chronic HBV infection (24). Since the HCV core region has several epitopes which play a crucial role in the immune response to HCV (25, 26), alterations or a deletion in this region in HD patients can operate on escape from immune pressure, leading to persistence of viral infection. Furthermore, the reduced immune defense resulting from an imbalance between cytokines and their inhibitors (16, 17) might also be involved in viral persistence in HD patients.

The time course analysis of the levels of viremia in HD patients with HCV represented a reduction of the levels of HCV-RNA immediately after HD procedure. However, the reduced levels were restored to the baseline values 2 days after the procedure. Similar results were described by Okuda et al, who reported that the levels of HCV-RNA in blood significantly decreased after each HD procedure (27). In addition, several groups have shown that, in contrast to patients with HCV who do not receive HD, fluctuation of the level of viremia is frequently observed in HD patients with HCV (20, 28). Hayashi et al have recently demonstrated the adsorption of HCV particles onto the dialyzer membrane (29), although the mechanism of the adsorption in which many factors including the size or the charge of viral particles or the presence of immunoglobulins associated with viral particles may be affected is not fully understood. This finding is likely to account for the transient reduction or fluctuation of the levels of HCV-RNA in the clinical course of HD patients with HCV.

In summary, alterations in the HCV sequence seem to be similar in patients who do and do not receive HD. Although the transient reduction of the levels of HCV-RNA during HD procedure occurs in a large proportion of patients, HCV is replicable in these patients. Worsening of the virus-associated liver inflammation after renal transplantation has often been recognized in HD patients with HCV (5, 15). Previous studies have shown that the frequency of HD patients with HCV who result in sustained response to interferon is similar to or relatively higher than that of patients who do not receive HD (30, 31). Taken together, the low pretreatment level of HCV-RNA is an important predictor of response to interferon in patients who do and do not receive HD (30–32). Thus, interferon treatment prior to renal transplantation is a possible strategy for the eradication of HCV in HD patients, particularly in those who have relatively low levels of viremia.

Acknowledgements: The authors thank M. Matsuo and T. Yoshikawa for skillful technical assistance.

References

HCV in Hemodialysis Patients


